Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
166.245 USD
0.96%
Market Closed
Updated:
Apr 19, 2024
Abbvie Inc
Long-Term Debt
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Long-Term Debt Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$52.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$23.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$63.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$376.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
31%
|
CAGR 10-Years
18%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Abbvie Inc's Long-Term Debt?
Long-Term Debt
52.2B
USD
52.2B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Long-Term Debt amounts to 52.2B USD.
What is Abbvie Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
14%
14%
Over the last year, the Long-Term Debt growth was -12%. The average annual Long-Term Debt growth rates for Abbvie Inc have been -12% over the past three years , 8% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
